International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 050-056
| Back | Table of Contents | PDF | Mail to Author | |
Evaluation of the Prognostic Role of Absolute Monocyte Count, Lymphocyte Monocyte Ratio and Neutrophil Lymphocyte Ratio in Hodgkin Lymphoma: Single Center Experience
Yasemin BOLUKBASI1,2, Duygu SEZEN1, Sukran SENYUREK1, Serdar ORNEK3, Ugur SELEK1,2, Burhan FERHANOGLU4
1Koc University, Faculty of Medicine, Department of Radiation Oncology, Istanbul, TURKEY
2The University of Texas, MD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX, USA
3American Hospital, Department of Hematology, Istanbul, TURKEY
4Koc University, Faculty of Medicine, Department of Hematology, Istanbul, TURKEY
Keywords: Lymphoma, Monocyte, prognosis
It is crucial to identify Hodgkin lymphoma (HL) patients who may have resistance to treatment in order to choose the best risk adapted strategy at the time of diagnosis. We evaluated whether AMC (Absolute monocyte count), ALC (Absolute lymphocyte count), Lymphocyte/ monocyte ratio (LMR), and Neutrophil Monocyte Ratio (NLR) were prognostic factors for HL. Sixty-five patients with classic Hodgkin Lymphoma were retrospectively reviewed. Initial peripheral blood tests were analyzed. Of the entire cohort, 96.9% (63) had complete or partial remission. The median overall survival was 144 and median progression free survival was 130.7 months. The median AMC and LMR for all patients were 0.8x103/UL and 2.1. There were no statistically significant cut-off value for AMC, ALC and LMR. Median NLR was 3.9 and had a statistically significant cut-off value as 4.38 (p= 0.002). Mean overall survival time with NLR < 4.38 was 151.8 months versus 117.2 months for patients with > 4.38 NLR (p= 0.047). Mean progression free survival time was also significantly longer for patients with NLR < 4.38 versus >4.38 (145.6 vs 102.8 months, p= 0.005). Increased NLR sound to be a poor prognostic indicator in our cohort. NLR might be considered an additive parameter in management decision tree.
Yasemin BOLUKBASI1,2, Duygu SEZEN1, Sukran SENYUREK1, Serdar ORNEK3, Ugur SELEK1,2, Burhan FERHANOGLU4
1Koc University, Faculty of Medicine, Department of Radiation Oncology, Istanbul, TURKEY
2The University of Texas, MD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX, USA
3American Hospital, Department of Hematology, Istanbul, TURKEY
4Koc University, Faculty of Medicine, Department of Hematology, Istanbul, TURKEY
Keywords: Lymphoma, Monocyte, prognosis
It is crucial to identify Hodgkin lymphoma (HL) patients who may have resistance to treatment in order to choose the best risk adapted strategy at the time of diagnosis. We evaluated whether AMC (Absolute monocyte count), ALC (Absolute lymphocyte count), Lymphocyte/ monocyte ratio (LMR), and Neutrophil Monocyte Ratio (NLR) were prognostic factors for HL. Sixty-five patients with classic Hodgkin Lymphoma were retrospectively reviewed. Initial peripheral blood tests were analyzed. Of the entire cohort, 96.9% (63) had complete or partial remission. The median overall survival was 144 and median progression free survival was 130.7 months. The median AMC and LMR for all patients were 0.8x103/UL and 2.1. There were no statistically significant cut-off value for AMC, ALC and LMR. Median NLR was 3.9 and had a statistically significant cut-off value as 4.38 (p= 0.002). Mean overall survival time with NLR < 4.38 was 151.8 months versus 117.2 months for patients with > 4.38 NLR (p= 0.047). Mean progression free survival time was also significantly longer for patients with NLR < 4.38 versus >4.38 (145.6 vs 102.8 months, p= 0.005). Increased NLR sound to be a poor prognostic indicator in our cohort. NLR might be considered an additive parameter in management decision tree.
| Back | Table of Contents | PDF | Mail to Author | |